For many years, researchers and public health specialists have been assessing the human health impact of prenatal exposure to the estrogenic anti-miscarriage drug, diethylstilbestrol (commonly known as DES or “stilbestrol”). The scope of adverse effects in females exposed to DES (often called “DES daughters“) has been more substantially documented than the effects in males (“DES sons“). This paper contributes three areas of important research on DES exposure in males:
- an overview of published literature discussing the confirmed and suspected adverse effects of prenatal exposure in DES sons;
- preliminary results from a 5-year online study of DES sons involving 500 individuals with confirmed (60% of sample) and suspected prenatal DES exposure;
- documentation of the presence of gender identity disorders and male-to-female transsexualism reported by more than 100 participants in the study.
Read the Full Paper prepared for the International Behavioral Development Symposium 2005, PRENATAL EXPOSURE TO DIETHYLSTILBESTROL (DES) IN MALES AND GENDER-RELATED DISORDERS: RESULTS FROM A 5-YEAR STUDY, by Scott P. Kerlin, Ph.D., DES Sons International Network, Aug 2005.
More DES DiEthylStilbestrol Resources
- DES studies on cancers and screening.
- DES studies on epigenetics and transgenerational effects.
- DES studies on fertility and pregnancy.
- DES studies on gender identity and psychological health.
- DES studies on in-utero exposure to DES and side-effects.
- DES studies on the genital tract.
- Papers on DES lawsuits.
- DES videos and posts tagged DES, the DES-exposed, DES victims.